BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 23201326)

  • 1. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
    Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
    Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digitized assessment of mammographic breast density--effects of continuous combined hormone therapy, tibolone and black cohosh compared to placebo.
    Lundström E; Hirschberg AL; Söderqvist G
    Maturitas; 2011 Dec; 70(4):361-4. PubMed ID: 21958943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women.
    Ziaei S; Moghasemi M; Faghihzadeh S
    Climacteric; 2010 Apr; 13(2):147-56. PubMed ID: 19731119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial.
    Nijland EA; Weijmar Schultz WC; Nathorst-Boös J; Helmond FA; Van Lunsen RH; Palacios S; Norman RJ; Mulder RJ; Davis SR;
    J Sex Med; 2008 Mar; 5(3):646-56. PubMed ID: 18304284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.
    Plumb JM; Guest JF
    Pharmacoeconomics; 2000 Nov; 18(5):477-86. PubMed ID: 11151401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction.
    Nijland EA; Nathorst-Böös J; Palacios S; van de Weijer PW; Davis S; Stathopoulos VM; Birkhaeuser MH; von Mauw E; Mulder RJ; Schultz WC;
    Climacteric; 2009 Apr; 12(2):114-21. PubMed ID: 19177255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women.
    Dahm AE; Eilertsen AL; Goeman J; Olstad OK; Ovstebø R; Kierulf P; Mowinckel MC; Skretting G; Sandset PM
    Thromb Res; 2012 Jul; 130(1):45-51. PubMed ID: 22217510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms.
    Hammar M; Christau S; Nathorst-Böös J; Rud T; Garre K
    Br J Obstet Gynaecol; 1998 Aug; 105(8):904-11. PubMed ID: 9746385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
    Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
    Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tibolone and raloxifene on health-related quality of life and sexual function.
    Nijland EA; Weijmar Schultz WC; Davis SR
    Maturitas; 2007 Oct; 58(2):164-73. PubMed ID: 17870260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
    Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
    BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women.
    Stuedal A; Ma H; Bjørndal H; Ursin G
    Climacteric; 2009 Jun; 12(3):248-58. PubMed ID: 19387884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy.
    Wu MH; Pan HA; Wang ST; Hsu CC; Chang FM; Huang KE
    Climacteric; 2001 Dec; 4(4):314-9. PubMed ID: 11770188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tibolone on climacteric symptoms and quality of life in breast cancer patients--data from LIBERATE trial.
    Sismondi P; Kimmig R; Kubista E; Biglia N; Egberts J; Mulder R; Planellas J; Moggio G; Mol-Arts M; Kenemans P
    Maturitas; 2011 Dec; 70(4):365-72. PubMed ID: 22030384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tibolone or continuous combined oestradiol and norethisterone acetate on lipids, high-density lipoprotein subfractions and apolipoproteins in postmenopausal women in a two-year, randomized, double-blind, placebo-controlled trial.
    Kotecha PT; Godsland IF; Crook D; Stevenson JC
    Clin Endocrinol (Oxf); 2020 Apr; 92(4):303-311. PubMed ID: 31925799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of continuous combined hormone therapy and tibolone on body composition in postmenopausal women.
    Ziaei S; Moaya M; Faghihzadeh S
    Climacteric; 2010 Jun; 13(3):249-53. PubMed ID: 19848555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.